| Literature DB >> 30301234 |
Ana Carolina Nazaré1, Carlos Roberto Polaquini2, Lúcia Bonci Cavalca3,4, Daiane Bertholin Anselmo5, Marilia de Freitas Calmon Saiki6, Diego Alves Monteiro7, Aleksandra Zielinska8, Paula Rahal9, Eleni Gomes10, Dirk-Jan Scheffers11, Henrique Ferreira12, Luis Octavio Regasini13.
Abstract
Xanthomonas citri subsp. citri (Xcc) causes citrus canker, affecting sweet orange-producing areas around the world. The current chemical treatment available for this disease is based on cupric compounds. For this reason, the objective of this study was to design antibacterial agents. In order to do this, we analyzed the anti-Xcc activity of 36 alkyl dihydroxybenzoates and we found 14 active compounds. Among them, three esters with the lowest minimum inhibitory concentration values were selected; compounds 4 (52 μM), 16 (80 μM) and 28 (88 μM). Our study demonstrated that alkyl dihydroxybenzoates cause a delay in the exponential phase. The permeability capacity of alkyl dihydroxybenzoates in a quarter of MIC was compared to nisin (positive control). Compound 28 was the most effective (93.8), compared to compound 16 (41.3) and compound 4 (13.9) by percentage values. Finally, all three compounds showed inhibition of FtsZ GTPase activity, and promoted changes in protofilaments, leading to depolymerization, which prevents bacterial cell division. In conclusion, heptyl dihydroxybenzoates (compounds 4, 16 and 28) are promising anti-Xcc agents which may serve as an alternative for the control of citrus canker.Entities:
Keywords: antimicrobial; citrus canker; membrane disruption; phenolic acids; plant disease
Mesh:
Substances:
Year: 2018 PMID: 30301234 PMCID: PMC6213047 DOI: 10.3390/ijms19103050
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Antibacterial activities against Xanthomonas citri subsp. citri, purity and log Po/w of dihydroxybenzoates 1–36.
| Entry | R | Purity | log | MIC μg mL−1 | MBC μg mL−1 | |
|---|---|---|---|---|---|---|
| Series I |
| H | 85.7 | 2.6 | >100 (>648) | >100 |
|
| CH2CH3 | 87.6 | 2.8 | >100 (>548) | >100 | |
|
| (CH2)3CH3 | 85.6 | 3.9 | 39.8 (189) | 50 | |
|
| (CH2)5CH3 | 81.7 | 5.0 | 20.0 (84) | 50 | |
|
| (CH2)6CH3 | 83.8 | 5.1 | 13.2 (52) | 25 | |
|
| (CH2)7CH3 | 79.6 | 6.1 | >100 (>375) | >100 | |
|
| (CH2)8CH3 | 99.0 | 6.2 | >100 (>356) | >100 | |
|
| (CH2)9CH3 | 99.5 | 6.9 | >100 (>340) | >100 | |
|
| (CH2)11CH3 | >99.9 | 7.0 | >100 (>310) | >100 | |
|
|
| 93.2 | 2.6 | >100 (>510) | >100 | |
|
|
| >99.9 | 2.2 | >100 (>450) | >100 | |
|
|
| >99.9 | 4.0 | 40.5 (171) | 100 | |
| Series II |
| H | 97.3 | 2.8 | >100 (>648) | >100 |
|
| CH2CH3 | 98.3 | 2.4 | >100 (>549) | >100 | |
|
| (CH2)3CH3 | 82.0 | 3.4 | >100 (>475) | >100 | |
|
| (CH2)5CH3 | 80.1 | 4.5 | 33.5 (140) | 50 | |
|
| (CH2)6CH3 | 99.3 | 5.0 | 20.2 (80) | 25 | |
|
| (CH2)7CH3 | 79.8 | 5.2 | >100 (>375) | >100 | |
|
| (CH2)8CH3 | >99.9 | 5.7 | >100 (>357) | >100 | |
|
| (CH2)9CH3 | 76.5 | 6.3 | >100 (>340) | >100 | |
|
| (CH2)11CH3 | >99.9 | 6.8 | >100 (>310) | >100 | |
|
|
| >99.9 | 2.2 | >100 (>510) | >100 | |
|
|
| >99.9 | 3.0 | 83.5 (375) | 100 | |
|
|
| >99.9 | 3.5 | 90.4 (382) | 100 | |
|
|
| >99.9 | 3.1 | 59.7 (231) | 100 | |
| Series III |
| H | 99.6 | 0.8 | >100 (>648) | >100 |
|
| CH2CH3 | 99.1 | 1.7 | >100 (>549) | >100 | |
|
| (CH2)3CH3 | 99.1 | 2.6 | >100 (>475) | >100 | |
|
| (CH2)5CH3 | 99.1 | 3.7 | 44.4 (186) | 50 | |
|
| (CH2)6CH3 | 98.5 | 4.3 | 22.2 (88) | 50 | |
|
| (CH2)7CH3 | 98.5 | 4.9 | 31.2 (117) | 50 | |
|
| (CH2)8CH3 | 97.9 | 5.5 | 26.7 (95) | 50 | |
|
| (CH2)9CH3 | 91.3 | 6.0 | >100 (>340) | 100 | |
|
| (CH2)11CH3 | >99.9 | 6.9 | >100 (>310) | >100 | |
|
|
| >99.9 | 1.4 | >100 (>510) | >100 | |
|
|
| >99.9 | 2.2 | >100 (>450) | >100 | |
|
|
| >99.9 | 2.7 | >100 (>423) | >100 | |
|
|
| >99.9 | 2.4 | 89.1 (345) | 100 | |
|
| 43.1 | - | ||||
|
| 19.9 (40) | - |
MIC—minimal inhibitory concentration; MBC—minimal bactericidal concentration.
IC50 value of compounds 4, 16 and 28 in μM against cell lines.
| Compounds | HaCaT | Huh-7,5 | MRC-5 | VERO | ACHN |
|---|---|---|---|---|---|
|
| 64.86 ± 8.91 a | 70.63 ± 5.52 a | 127.45 ± 4.59 b,c,h | 111.4 ± 8.34 c,f,h | 152.9 ± 7.07 d |
|
| 69.81 ± 4.87 a | 20.60 ± 0.23 e | 144.8 ± 6.29 b,d | 93.55 ± 1.93 f | 140.35 ± 7.56 b,d |
|
| 74.02 ± 11.74 a,g | 64.84 ± 14.91 a | 128.7 ± 2.12 b,c,h | 92.31 ± 9.34 f,g | 114.05 ± 9.97 g |
|
| >200 i | >200 i | >200 i | >200 i | >200 i |
|
| >200 i | >200 i | >200 i | >200 i | >200 i |
Different letters indicate statistical significance p < 0.05 in Tukey’s multiple comparisons test.
Figure 1Growth curve profiles of Xanthomonas citri subsp. citri with treatments in MIC and ½ MIC values of alkyl dihydroxybenzoates for 72 h. A Compound 4, B compound 16, C compound 28, and D copper oxychloride (CO) in comparison to control (untreated) and DMSO (vehicle control).
Figure 2Cellular permeability evaluation in the presence of alkyl dihydroxybenzoates (**** p < 0.0001, ANOVA with Dunnett’s post-test), ns = not significant.
Figure 3Optical microscopy of fluorescence images at ¼ MIC of alkyl dihydroxybenzoates for 15 min. (A) Negative control (untreated), (B) vehicle control (DMSO), (C) positive control (nisin), (D) compound 4, (E) compound 16, and (F) compound 28.
Scheme 1Preparation of alkyl dihydroxybenzoates by Fischer’s Esterification.
Figure 4Inhibition of GTPase activity of alkyl dihydroxybenzoates in MIC value (* p < 0.04, ** p < 0.001, **** p < 0.0001, ANOVA with Dunnett’s post-test).